SCHEMBL1414008

SCHEMBL1414008

COC(=O)c1cc(-c2ccc(OC)cc2)n[nH]1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 1.00
ALPL P05186 5/20 1.00
RAB9A P51151 5/20 1.00
NPC1 O15118 4/20 1.00
LMNA P02545 2/20 1.00
SMN1; SMN2 Q16637 2/20 1.00
CA9 Q16790 1/20 0.76
POLB P06746 1/20 0.76
L3MBTL1 Q9Y468 1/20 0.75
ALDH1A1 P00352 2/20 0.74
GAA P10253 1/20 0.73
ACR P10323 1/20 0.67
HDAC3 O15379 2/20 0.64
HDAC4 P56524 2/20 0.64
HDAC1 Q13547 2/20 0.64
HDAC7 Q8WUI4 2/20 0.64
HDAC2 Q92769 2/20 0.64
HDAC10 Q969S8 2/20 0.64
HDAC11 Q96DB2 2/20 0.64
HDAC8 Q9BY41 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14152359 0.86 ALPL (1.00) MAPTALPLRAB9ANPC1LMNA
SCHEMBL2888912 0.86 MAPT (1.00) MAPTALPLRAB9ANPC1LMNA
SCHEMBL2631731 0.85 MAPT (1.00) MAPTALPLRAB9ANPC1LMNA
SCHEMBL2848443 0.85 ALPL (0.76) MAPTALPLRAB9ANPC1LMNA
SCHEMBL855912 0.85 ALPL (0.76) MAPTALPLRAB9ANPC1LMNA
SCHEMBL2524441 0.85 ALPL (0.76) MAPTALPLRAB9ANPC1LMNA
SCHEMBL646099 0.84 GAA (1.00) MAPTALPLRAB9ANPC1LMNA
SCHEMBL1413966 0.84 ALPL (1.00) MAPTALPLRAB9ANPC1LMNA
SCHEMBL4788746 0.83 GAA (0.75) MAPTALPLRAB9ANPC1LMNA
Hydrochloric Acid SCHEMBL1314014 0.83 GAA (0.97) MAPTALPLRAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2291372-A2 INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF Burnham Institute for Medical Research (US) 2011-03-09 EP disclosed
WO-2010046780-A2 ANTI VIRAL COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2010-04-29 WO disclosed
US-20100016313-A1 INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-01-21 US disclosed
US-20100016313-A1 INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-01-21 US disclosed
US-20100016313-A1 INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-01-21 US disclosed
WO-2009143150-A2 INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016313-A1 INTESTINAL ALKALINE PHOSPHATASE MODULATORS AND USES THEREOF ALPI, SI, FABP2 MAPT 4675/4885ALPL 5/4885RAB9A 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.